Jonathan D. Schoenfeld, MD, MPhil, MPH

Jonathan D. Schoenfeld, MD, MPhil, MPH

Radiation Oncology

Contact Information

Office Phone Number

617-632-5296

Fax

617-394-2667

Biography

Jonathan D. Schoenfeld, MD, MPhil, MPH

Dr. Jonathan Schoenfeld is an Associate Professor at Harvard Medical School, Director of Head and Neck and Melanoma Radiation Oncology at Dana-Farber Brigham Cancer Center, and MGB Endowed Chair in Radiation Oncology.  He is a Senior Physician at Dana-Farber Cancer Institute and a member of the Cancer Immunology Program. He also serves as Associate Director of Clinical Research within the Department of Radiation Oncology.

Dr. Schoenfeld received his medical degree from Harvard Medical School after completing a research fellowship as a Gates Scholar at the University of Cambridge in the UK. He performed his medical internship at Memorial Sloan Kettering Cancer Center, then completed residency in radiation oncology in the Harvard Radiation Program. He received a Master of Public Health in Clinical Effectiveness from the Harvard T.H. Chan School of Public Health.  

His research involves clinical trials involving radiation and integration with immunotherapy and other novel systemic therapies and innovative radiation techniques.  Additionally, he leads trials integrating biomarkers such as circulating tumor DNA that predict response to radiation or immune therapies. 

Researcher

Physician

Director, Melanoma Radiation Oncology
Senior Physician
Associate Professor of Radiation Oncology, Harvard Medical School
Director, Head and Neck Radiation Oncology

Centers/Programs

Thyroid Cancer Program

Clinical Interests

Head and neck cancers, Melanoma, Skin cancer, Tumor immunology

Fellowship

  • Harvard School of Public Health
  • University of Cambridge, UK

Residency

  • Harvard Radiation Program, Radiation Oncology

Medical School

  • Harvard Medical School

Publications

    • Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence. Cancer. 2024 Aug 05. View in: Pubmed

    • Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2024 Aug 01; 30(15):3329-3336. View in: Pubmed

    • Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck. Cancer Treat Rev. 2024 Jun 01; 129:102773. View in: Pubmed

    • Patterns of metastasis from a multicenter cohort of metastatic basal cell carcinoma. J Am Acad Dermatol. 2024 Jun; 90(6):1252-1254. View in: Pubmed

    • AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors. Nanoscale. 2024 Feb 01; 16(5):2347-2360. View in: Pubmed

    • In Reply to Fabi. Adv Radiat Oncol. 2024 Jan; 9(1):101381. View in: Pubmed

    • Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design. Future Oncol. 2024 Apr; 20(12):739-748. View in: Pubmed

    • The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1404-1421. View in: Pubmed

    • A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma. J Am Acad Dermatol. 2024 Mar; 90(3):545-551. View in: Pubmed

    • A multicenter real-world analysis of first-line systemic monotherapy for locally advanced basal cell carcinoma. JAAD Case Rep. 2023 Dec; 42:69-71. View in: Pubmed

    • Outcomes of palliative radiation therapy for cutaneous squamous cell carcinoma: A retrospective cohort study. JAAD Int. 2024 Mar; 14:26-28. View in: Pubmed

    • Proceed With Caution: Eliminating Elective Nodal Irradiation With Immunotherapy for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):355-356. View in: Pubmed

    • Definitive radiation therapy for inoperable stage III/IV cutaneous squamous cell carcinoma: A single-institution retrospective cohort study. J Am Acad Dermatol. 2024 01; 90(1):187-189. View in: Pubmed

    • Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci Immunol. 2023 09 08; 8(87):eadf4968. View in: Pubmed

    • Lost in the shadow of giants: The neglected treatment modalities in oncologic trials. Cancer. 2023 Nov 01; 129(21):3357-3359. View in: Pubmed

    • A multicenter retrospective cohort analysis of advanced basal cell carcinoma outcomes by sex. J Am Acad Dermatol. 2024 01; 90(1):137-139. View in: Pubmed

    • Development and Validation of an Automated Image-Based Deep Learning Platform for Sarcopenia Assessment in Head and Neck Cancer. JAMA Netw Open. 2023 08 01; 6(8):e2328280. View in: Pubmed

    • Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent Literature. Adv Radiat Oncol. 2024 Jan; 9(1):101310. View in: Pubmed

    • Radiotherapy Dose in Patients Receiving Immunotherapy. Semin Radiat Oncol. 2023 07; 33(3):327-335. View in: Pubmed

    • Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digit Health. 2023 06; 5(6):e360-e369. View in: Pubmed

    • Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline. medRxiv. 2023 Mar 06. View in: Pubmed

    • Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension. Eur Radiol. 2023 May; 33(5):3693-3703. View in: Pubmed

    • Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2022 12 01; 148(12):1120-1130. View in: Pubmed

    • Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treat Rev. 2023 Feb; 113:102492. View in: Pubmed

    • Image quality comparisons of coil setups in 3T MRI for brain and head and neck radiotherapy simulations. J Appl Clin Med Phys. 2022 Dec; 23(12):e13794. View in: Pubmed

    • Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022 08 04; 185(16):2918-2935.e29. View in: Pubmed

    • Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):666-675. View in: Pubmed

    • Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiother Oncol. 2022 08; 173:32-40. View in: Pubmed

    • Unusual presentation of HPV-positive squamous cell carcinoma of the nasolacrimal duct as carcinoma of unknown primary. Am J Otolaryngol. 2022 May-Jun; 43(3):103457. View in: Pubmed

    • Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 06; 44(6):1442-1452. View in: Pubmed

    • Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. J Am Acad Dermatol. 2022 07; 87(1):87-94. View in: Pubmed

    • Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngol Head Neck Surg. 2022 Mar 01; 148(3):268-276. View in: Pubmed

    • Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May; 18(14):1669-1678. View in: Pubmed

    • Technical note: Toward implementation of MR-guided radiation therapy for laryngeal cancer with healthy volunteer imaging and a custom MR-CT larynx phantom. Med Phys. 2022 Mar; 49(3):1814-1821. View in: Pubmed

    • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291. View in: Pubmed

    • Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. J Immunother Cancer. 2022 01; 10(1). View in: Pubmed

    • Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors. Adv Radiat Oncol. 2022 Mar-Apr; 7(2):100880. View in: Pubmed

    • Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734. View in: Pubmed

    • Imaging features, therapies, and outcomes of fibrosing inflammatory pseudotumor of the nasopharynx: A systematic review. J Neuroimaging. 2022 Mar; 32(2):223-229. View in: Pubmed

    • Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478. View in: Pubmed

    • Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. J Immunother. 2021 10 01; 44(8):307-318. View in: Pubmed

    • Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4940. View in: Pubmed

    • Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition. Int J Radiat Oncol Biol Phys. 2021 12 01; 111(5):1165-1175. View in: Pubmed

    • Personalized Radiation Attenuating Materials for Gastrointestinal Mucosal Protection. Adv Sci (Weinh). 2021 06; 8(12):2100510. View in: Pubmed

    • Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021 04; 9(4). View in: Pubmed

    • A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 05 01; 27(9):2470-2480. View in: Pubmed

    • The effects of releasing early results from ongoing clinical trials. Nat Commun. 2021 02 05; 12(1):801. View in: Pubmed

    • Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. Front Oncol. 2020; 10:608772. View in: Pubmed

    • Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab-Reply. JAMA Oncol. 2021 02 01; 7(2):309-310. View in: Pubmed

    • Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2021 Jan 01; 27(1):357. View in: Pubmed

    • Reply to "Keynote 48: Is it really for everyone?" Oral Oncol. 2021 04; 115:105108. View in: Pubmed

    • Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. Adv Radiat Oncol. 2021 May-Jun; 6(3):100608. View in: Pubmed

    • Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. J Am Acad Dermatol. 2021 Mar; 84(3):875-877. View in: Pubmed

    • Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087. View in: Pubmed

    • Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. JCO Precis Oncol. 2020 Nov; 4:1196-1206. View in: Pubmed

    • Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570. View in: Pubmed

    • Radiation-Induced Hypothyroidism in Patients with Oropharyngeal Cancer Treated with IMRT: Independent and External Validation of Five Normal Tissue Complication Probability Models. Cancers (Basel). 2020 Sep 22; 12(9). View in: Pubmed

    • Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020 12 15; 126(24):5274-5282. View in: Pubmed

    • Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677. View in: Pubmed

    • A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144. View in: Pubmed

    • Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 10 01; 26(19):5140-5152. View in: Pubmed

    • Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762. View in: Pubmed

    • Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. World Neurosurg. 2020 07; 139:226-231. View in: Pubmed

    • The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608. View in: Pubmed

    • Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690. View in: Pubmed

    • Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676. View in: Pubmed

    • A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):238-245. View in: Pubmed

    • Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer. 2020 04 01; 126(7):1424-1433. View in: Pubmed

    • Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Dis. 2020 Mar; 26(2):325-333. View in: Pubmed

    • Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222. View in: Pubmed

    • Immunotherapy and Radiation: Charting a Path Forward Together. Hematol Oncol Clin North Am. 2019 12; 33(6):1057-1069. View in: Pubmed

    • Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs. Clin Cancer Res. 2019 12 15; 25(24):7281-7286. View in: Pubmed

    • PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Transl Lung Cancer Res. 2019 Sep; 8(Suppl 2):S139-S146. View in: Pubmed

    • Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667. View in: Pubmed

    • A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139. View in: Pubmed

    • Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 04 24; 7(1):112. View in: Pubmed

    • Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Front Oncol. 2019; 9:199. View in: Pubmed

    • Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89. View in: Pubmed

    • Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106. View in: Pubmed

    • Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. Head Neck. 2019 07; 41(7):2111-2115. View in: Pubmed

    • Radiation Therapy and Immune Modulation. Hematol Oncol Clin North Am. 2019 04; 33(2):233-248. View in: Pubmed

    • IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966. View in: Pubmed

    • Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies. Clin Chem. 2018 12; 64(12):1762-1771. View in: Pubmed

    • The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151. View in: Pubmed

    • We Are All Connected: Modeling the Tumor-Immune Ecosystem. Trends Cancer. 2018 10; 4(10):655-657. View in: Pubmed

    • Immunotherapy and radiotherapy for metastatic cancers. Ann Palliat Med. 2019 Jul; 8(3):312-325. View in: Pubmed

    • Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34. View in: Pubmed

    • Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. JAMA Oncol. 2018 08 01; 4(8):1123-1124. View in: Pubmed

    • Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145. View in: Pubmed

    • Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):34-43. View in: Pubmed

    • Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1259-1270. View in: Pubmed

    • Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy. N Engl J Med. 2018 03 22; 378(12):1158-1159. View in: Pubmed

    • Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4). View in: Pubmed

    • Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018 05; 18(5):313-322. View in: Pubmed

    • Potential Role of the Quality Assurance Review Center Platform in Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):956-962. View in: Pubmed

    • The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413. View in: Pubmed

    • Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165. View in: Pubmed

    • Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191. View in: Pubmed

    • Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103. View in: Pubmed

    • Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy. Converg Sci Phys Oncol. 2017 Sep; 3(3). View in: Pubmed

    • Prospective analysis of radiation oncology image and plan-driven peer review for head and neck cancer. Head Neck. 2017 08; 39(8):1603-1608. View in: Pubmed

    • The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350. View in: Pubmed

    • Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69. View in: Pubmed

    • Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):344-351. View in: Pubmed

    • Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136. View in: Pubmed

    • Merkel Cell Carcinoma: A Population Analysis on Survival. J Natl Compr Canc Netw. 2016 10; 14(10):1247-1257. View in: Pubmed

    • Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26. View in: Pubmed

    • Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60. View in: Pubmed

    • Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32. View in: Pubmed

    • Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87. View in: Pubmed

    • The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. Am J Clin Oncol. 2016 06; 39(3):243-7. View in: Pubmed

    • Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8. View in: Pubmed

    • Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 2016 06; 19(2):197-201. View in: Pubmed

    • Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. BJR Case Rep. 2016; 2(1):20150271. View in: Pubmed

    • Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49. View in: Pubmed

    • Radiation dose and checkpoint blockade immunotherapy: unanswered questions. Lancet Oncol. 2016 Jan; 17(1):e3-4. View in: Pubmed

    • Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015; 3:50. View in: Pubmed

    • Radiation Oncology--New Approaches in Squamous Cell Cancer of the Head and Neck. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1093-106. View in: Pubmed

    • A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 Nov; 4(11):e1046028. View in: Pubmed

    • Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer. 2015 Aug 01; 121(15):2594-602. View in: Pubmed

    • Immune effects of targeted radiation therapy for cancer. Discov Med. 2015 Mar; 19(104):219-28. View in: Pubmed

    • Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4. View in: Pubmed

    • Immunity in head and neck cancer. Cancer Immunol Res. 2015 Jan; 3(1):12-7. View in: Pubmed

    • Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100. View in: Pubmed

    • Reply to 'Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer' by T. Kawada. Ann Oncol. 2014 Feb; 25(2):543-4. View in: Pubmed

    • Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol. 2013 Jun; 24(6):1427-34. View in: Pubmed

    • A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9. View in: Pubmed

    • Is everything we eat associated with cancer? A systematic cookbook review. Am J Clin Nutr. 2013 Jan; 97(1):127-34. View in: Pubmed

    • PET/CT of cancer patients: part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer. AJR Am J Roentgenol. 2012 Nov; 199(5):968-74. View in: Pubmed

    • Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report. Anticancer Res. 2012 May; 32(5):1743-6. View in: Pubmed

    • Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Ann Oncol. 2012 Jul; 23(7):1813-8. View in: Pubmed

    • Abbreviated course of radiotherapy (RT) for breast cancer. Breast. 2011 Oct; 20 Suppl 3:S116-27. View in: Pubmed

    • Anti-angiogenesis immunotherapy. Hum Vaccin. 2011 Sep; 7(9):976-81. View in: Pubmed

    • Colorectal cancer in African American and Caucasian patients: A comparison of an urban, university hospital with the National Cancer Institute SEER database. J Clin Oncol. 2011 May 20; 29(15_suppl):3631. View in: Pubmed

    • Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease. J Clin Oncol. 2011 Feb; 29(4_suppl):110. View in: Pubmed

    • Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60. View in: Pubmed

    • Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14. View in: Pubmed

    • PECAM-1 affects GSK-3beta-mediated beta-catenin phosphorylation and degradation. Am J Pathol. 2006 Jul; 169(1):314-24. View in: Pubmed

    • Identification of the regions of PECAM-1 involved in beta- and gamma-catenin associations. Biochem Biophys Res Commun. 2005 Apr 22; 329(4):1225-33. View in: Pubmed

    • Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. Angiogenesis. 2004; 7(2):143-56. View in: Pubmed

    • PECAM-1 promotes beta-catenin accumulation and stimulates endothelial cell proliferation. Biochem Biophys Res Commun. 2003 Mar 28; 303(1):212-8. View in: Pubmed

    Locations

    Location Avtar

    Brigham and Women's Hospital

    75 Francis Street Boston, MA 02115
    Get Directions
    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Brigham and Women's Hospital

    Location Avtar

    Brigham and Women's Hospital

    75 Francis Street Boston, MA 02115
    Get Direction
    42.3362, -71.1067

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Jonathan D. Schoenfeld, MD, MPhil, MPH

    About Our Ratings

    Physician Star Rating Comment Block